Contrasting Cyclacel Pharmaceuticals (BGMS) & Its Rivals

Cyclacel Pharmaceuticals (NASDAQ:BGMS) is one of 451 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its competitors? We will compare Cyclacel Pharmaceuticals to related businesses based on the strength of its earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Profitability

This table compares Cyclacel Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-187.37%	-106.68%
Cyclacel Pharmaceuticals Competitors	-2,626.20%	-359.54%	-43.35%

Analyst Recommendations

This is a summary of current recommendations and price targets for Cyclacel Pharmaceuticals and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1	0	0	0	1.00
Cyclacel Pharmaceuticals Competitors	4862	9974	15986	376	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 121.85%. Given Cyclacel Pharmaceuticals’ competitors stronger consensus rating and higher possible upside, analysts clearly believe Cyclacel Pharmaceuticals has less favorable growth aspects than its competitors.

Volatility & Risk

Cyclacel Pharmaceuticals has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals’ competitors have a beta of 11.33, indicating that their average stock price is 1,033% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cyclacel Pharmaceuticals and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$40,000.00	-$11.21 million	-0.02
Cyclacel Pharmaceuticals Competitors	$434.35 million	-$68.27 million	-10.93

Cyclacel Pharmaceuticals’ competitors have higher revenue, but lower earnings than Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Cyclacel Pharmaceuticals competitors beat Cyclacel Pharmaceuticals on 8 of the 13 factors compared.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.